Using alanyl-glutamine to improve treatment for C. difficile infection
Alanyl-glutamine supplementation of standard treatment for C. difficile infection
This study is looking at whether taking a supplement called alanyl-glutamine can help people with C. difficile infections feel better and stay healthy after treatment, and it will find out the best dose and how safe it is for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10880550 on NIH RePORTER |
What this research studies
This research investigates the potential of alanyl-glutamine supplementation to enhance the effectiveness of standard treatments for C. difficile infection (CDI). The study will involve a randomized, double-blinded, placebo-controlled trial to determine the optimal dosage of alanyl-glutamine and assess its safety. Researchers aim to evaluate how this supplementation can prevent recurrence of CDI and improve intestinal health in patients. By examining its effects on inflammation, barrier function, and gut flora, the study seeks to provide a comprehensive understanding of alanyl-glutamine's benefits in CDI treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults who have been diagnosed with C. difficile infection and are undergoing standard antibiotic treatment.
Not a fit: Patients who are not currently experiencing C. difficile infection or those who are not receiving standard antibiotic treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the recurrence rates of C. difficile infections and improve overall patient outcomes.
How similar studies have performed: Previous pilot studies have shown promising results with alanyl-glutamine in preventing recurrent CDI, indicating potential for success in this larger trial.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Warren, Cirle Alcantara — University of Virginia
- Study coordinator: Warren, Cirle Alcantara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.